Gritgen Therapeutics

Focus: Gritgen Therapeutics is a gene therapy biotech focused on rare genetic diseases, headquartered in Suzhou, China. Founded in 2019, the company is in early-stage development with a lean, emerging pipeline.

Gene Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

SERIES A

Open Jobs

About Gritgen Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Gritgen Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

GS1168 injection

Phenylketonuria (PKU)

Phase 1

Clinical Trials (1)

NCT07318909To Evaluate the Safety and Efficacy of GS1168 Injection in Adult Phenylketonuria

Phase 1

Help build intelligence for Gritgen Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to build gene therapy programs from the ground up in an emerging therapeutic area with high clinical value
Early-stage Series A company offers potential for meaningful scientific contribution and accelerated career progression in a growing field
China-based biotech with access to Asian markets and patient populations for rare genetic diseases

Watch Out For

Pre-revenue stage with unknown funding trajectory creates financial stability risk; no disclosed Series A funding amount raises sustainability concerns
Zero active job openings and minimal publicly disclosed team size suggest slow hiring and limited immediate career movement

Generated by Claude from Gritgen Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

GS1191-0445 injection

Hemophilia A

Phase 3

Clinical Trials (2)

NCT06833983To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A

Phase 3

NCT07548411To Evaluate the Safety and Efficacy of GS1191-0445 Injection in the Treatment of Severe Hemophilia A

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2019

Portfolio: 3 clinical trials

Top TAs: Rare Diseases

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Rare Diseases

3 pipeline

Marketed

Pipeline